Breaking News, Collaborations & Alliances

AmpliPhi, U.S. Army in Global R&D Pact

To develop therapies to treat resistant bacterial infections

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AmpliPhi BioSciences has entered a Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR) to develop and commercialize bacteriophage therapeutics to treat Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa infections. The initial indication will be wounds and skin infections from S.aureus, which accounts for 30% of surgical site infections.   AmpliPhi will r...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters